By: Caitlin A. Koppenhaver, Attorney with Florida Healthcare Law Firm and Chief Industry Advisor to APA
FDA’s March 5, 2026 warning letter to Novo Nordisk is a useful reminder that compliance risk is not confined to compounders or to any single segment of the market. In this case, FDA cited serious violations relating to postmarketing adverse drug experience (PADE) reporting, including deficiencies in written procedures, failures to report certain serious and unexpected adverse drug experiences to FDA within required timeframes, and deficiencies in quality control oversight of contractors performing delegated pharmacovigilance functions .
The takeaway should not be to diminish the importance of oversight in any setting. It should be to reinforce a more balanced principle that quality is a systems issue, not a categorical label. Pharmacies engaged in patient-specific compounding serve an important function, especially where individualized medication needs cannot be met by commercially available products. At the same time, manufacturers, outsourcing facilities, pharmacies, and others involved in the drug supply chain remain responsible for building and maintaining compliant, reliable quality systems.
For those of us who work in and around this space, the better conversation is not whether one sector is inherently “safe” and another is inherently “suspect.” The better conversation is whether the entity in question is operating with the level of rigor, documentation, oversight, and accountability that patient safety demands. FDA’s letter is a reminder that no segment of the industry is exempt from that responsibility